ClinicalTrials.gg
CompletedNCT00002404Updated Jan 29, 2008

The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected Patients

An interventional study of Valacyclovir hydrochloride in Herpes Simplex and HIV Infections, sponsored by Glaxo Wellcome. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-01-29.

Primary conditionHerpes GenitalisRegistry: Herpes SimplexReclassifiedWhy we changed it
Registry
Herpes Simplex — the first condition term the registry derived for this study.
ClinicalTrials.gg
Herpes Genitalis
Why
  1. The study's title name Herpes Genitalis, a narrower term within Herpes Simplex.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing valacyclovir in Herpes Genitalis — none open to participants now, none under way, none of them phase 3. Valacyclovir · Herpes Genitalis.

Enrollment
9th of 11
30 · median 50
No phase
5 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
4 of 14
Glaxo Wellcome

Among the 14 studies testing valacyclovir in Herpes Genitalis, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is one of 5 with no phase, and was the 1st registered.

Herpes Genitalis

70 studies on the registry are indexed under Herpes Genitalis; 3 are open to participants now.

Browse Herpes Genitalis studies →

Open to participants now

None of the 14 studies testing valacyclovir in Herpes Genitalis is open now. The open studies under Herpes Genitalis, anywhere →

About valacyclovir

Valacyclovir: first FDA approval 1995 (VALTREX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1 Herpes Genitalis study recruiting now, none set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing valacyclovir in Herpes Genitalis as a file.
02

Study summary

The purpose of this study is to see if valacyclovir affects the detection of HIV in genital herpes lesions in HIV-infected patients. Valacyclovir is used to treat recurrent genital herpes.

Read the detailed description

Following evaluation for 2 consecutive episodes of genital herpes in this double-blind, crossover study, 30 HIV-1 positive patients are randomized to receive either valacyclovir or placebo.

All patients are treated for 10 days.

03

Conditions studied

  • Herpes Simplex
  • HIV Infections

Browse trials for

Keywords

  • HIV-1
  • Antiviral Agents
  • Herpes Genitalis
  • Recurrence
  • DNA, Viral
  • RNA, Viral
  • valacyclovir
  • Herpesvirus 2, Human
04

In context

Herpes Genitalis Reclassified

70 studies on the registry are indexed under Herpes Genitalis; 3 are open to participants now.

This study's enrollment of 30 is below the median of 103 across 51 interventional studies indexed under Herpes Genitalis.

Browse Herpes Genitalis studies →

Lead sponsor

Glaxo Wellcome is the lead sponsor of 72 studies on the registry; none are open to participants now.

First submitted before Glaxo Wellcome became part of GlaxoSmithKline.

Compared within Herpes Genitalis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Herpes Simplex. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • Serologically documented HSV-2 and -1 infection.
  • History of recurrent genital herpes that presents at least 3 recurrences within the 12 months prior to the start of study.
  • No to valacyclovir.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  1. Hepatic impairment.
  2. Impaired renal function (creatinine above 2 mg/dl).
  3. Malabsorption syndrome or other gastrointestinal dysfunction.
  4. Any other condition that in the investigator's opinion would interfere with study procedures or successful completion of protocol.

Patients with the following prior conditions are excluded:

History of to acyclovir or valacyclovir.

Prior Medication:

Excluded:

  • Participation in any drug trial within 1 month prior to entry on study.
  • Systemic anti-HSV therapy within 7 days prior to start of study drug.

    1. Probenecid.
  • Suppressive treatment with medication that has anti-HSV activity.

Required:

  • Stable antiretroviral therapy or no therapy for at least 1 month.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Masking
Double
Enrollment
30 participants
07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 29, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00002404
Lead sponsor
Glaxo Wellcome
First posted
Aug 31, 2001
Last update
Jan 29, 2008
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 1999. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valacyclovir

Start the discussion